Press Releases

Company has received DCG(i) approval for 2-Deoxy-D-Glucose (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare Limited, API facility in Raichur, Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana. 2-Deoxy-D-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name ‘2-DGSHIL’.